Biotech called the shots in the Bay Area’s year-end capital scramble, with the single largest sale in the region clocking in ...

Here’s what was behind the recent sale of a former San Rafael biotech facility, a Santa Rosa distiller’s cautiously bold sublease, a Santa Rosa eye treatment center relocation, a San Rafael ...

Climate-resilient agriculture uses biotechnology, biofertilizers, biopesticides, genome-edited crops, and AI-driven tools to ...

In the rapidly evolving landscape of modern biotechnology, the precision of molecular tools determines the speed of medical breakthroughs. As a Global Leading Biotinylated Peptide Synthesis specialist ...

Corcept stock tanks as FDA setback hits relacorilant for Cushing’s syndrome. Truist analysts believe CORT shares pullback may ...

Matthew Herper covers medical innovation — both its promise and its perils. It has been a tough year for medicine. The U.S.

Prime Medicine Inc. (NASDAQ: PRME) is one of the best biotech penny stocks to buy according to analysts. On December 23, LifeSci Capital initiated coverage of Prime Medicine with an Outperform rating ...

The performance metrics speak volumes. The iShares Biotechnology ETF (NASDAQ: IBB) has climbed 29.51% year to date through December 29, while the State Street SPDR S&P Biotech ETF (NASDAQ: XBI) has ...

Small and mid-cap biotech stocks entered 2025 like a compressed spring, and it finally snapped higher— here's why.

In one of the rockiest years yet for science, Philadelphia-area researchers still managed to celebrate many wins. Here are five of them.

Two phase III studies of setrusumab, Orbit and Cosmic, for treating brittle bones have failed and left the developers floundering on Wall Street. Neither of Ultragenyx Pharmaceutical Inc. and Mereo ...

The Dubai Genome Program sequenced almost one million UAE citizens’ genomes by mid-2024. One million. That’s a ...